Abstract:Abstract Funding Acknowledgements Type of funding sources: None. Background Insomnia is highly prevalent in coronary heart disease (CHD) patients. However, the potential effect of insomnia on the risk of recurrent major adverse cardiovascular events (MACE) remains uncertain. Purpose To estimate the prospective association of insomnia and the risk of recurrent MACE in a CHD population from routine clinical practice. Methods This prospective cohort study included 1082 consecutive patients 2-36 (mean 16) months after a myocardial infarction and/or a coronary revascularization procedure. Data on insomnia, coronary risk factors and comorbidity were collected at baseline. Insomnia was assessed by Bergen insomnia scale (BIS), based on sleep symptoms per week during the past three months. BIS is constructed from the clinical diagnostic criteria for primary insomnia in DSM-IV TR. The primary composite endpoint of MACE defined as cardiovascular death, hospitalization due to myocardial infarction, revascularization, stroke or heart failure was obtained from the hospital records on average 4.2 (SD 0.3) years after the baseline study. Data were analysed using Cox proportional hazard regression on a multiple imputated dataset stratified by prior coronary events. Results At baseline, mean age was 62 (range 31-80) years, 21% were females, 90% were revascularized, 47% had participated in cardiac rehabilitation and the prescription rate of antiplatelets (97%) and statins (93%) were high. A total of 364 MACE (21%, 95% CI 19%-24%) occurred in 225 patients, including 39 CV deaths. Almost half of the patients (45%) suffered from insomnia at baseline and 24% used sleep medication the past week. For insomnia, the relative risk (RR) of recurrent MACE was 1.62 (95% confidence interval (CI) 1.24-2.11, p-value<0.001) in age and gender adjusted analysis, 1.49 (95% CI 1.14, 1.97, p-value=0.004) in analysis also adjusted for coronary risk factors and 1.48 (95% CI 1.12, 1.96, p-value=0.006) in a multi-adjusted analysis including age, gender, coronary risk factors and cardiovascular comorbidity. When also adjusted for symptoms of anxiety and depression the RR of insomnia on recurrent MACE remained significant at 1.41 (95% CI 1.05, 1.89, p-value=0.023). Insomnia accounted for 16% of the MACE in attributable risk fraction analyses, being third in importance after smoking (27%) and low physical activity (21%). Obstructive sleep apnea (Berlin Questionnaire) was not associated with recurrent MACE. Conclusions Insomnia was associated with increased risk of recurrent MACE in this prospective cohort following CHD patients from routine clinical practice. The association remained significant even after adjustments for the major coronary risk factors, comorbidity and symptoms of anxiety and depression, indicating that the effects of insomnia is not mediated through poor risk factor control and other psychosocial factors alone. These results emphasize the importance of identifying patients with insomnia as part of coronary rehabilitation.

Cardiovascular Risk Factors for the Diagnosis of Insomnia in End-Stage Renal Disease

Insomnia in patients on incident maintenance dialysis and the risk of major acute cardio-cerebrovascular events and all-cause mortality

Sleep apnea in end-stage renal disease patients: Impact on cardiovascular and neurological outcomes

Risk Factors for Sleep Disorders in Patients Undergoing Peritoneal Dialysis

Insomnia severity in chronic kidney disease patients with various therapies

Emerging Treatments for Insomnia, Sleep Apnea, and Restless Leg Syndrome Among Dialysis Patients

Associations between sleep problems and cardiometabolic risk in maintenance hemodialysis patients: A multicenter study

Sleep disorders in chronic kidney disease

Insomnia in chronic renal patients on dialysis in Saudi Arabia

Sleep Disorders and Cognitive Impairment in Peritoneal Dialysis: A Multicenter Prospective Cohort Study.

A systematic review of sleep disorders in patients with chronic kidney disease undergoing hemodialysis

Exploring sleep disorders in patients with chronic kidney disease

Association of Sleep Duration, Symptoms, and Disorders With Mortality in Adults With Chronic Kidney Disease

Impact of Hemodialysis on Sleep Disorders in Patients With End-Stage Renal Disease in a Tertiary Care Academic Hospital

The Effects of Insomnia and Sleep Loss on Cardiovascular Disease

Sleep-HD trial: short and long-term effectiveness of existing insomnia therapies for patients undergoing hemodialysis

An investigation of cardiac indices in normal sleepers and those with insomnia disorder

Insomnia was associated with increased risk of recurrent cardiovascular events in coronary heart disease patients

Residual kidney function and sleep quality in hemodialysis patients

Multiple, objectively measured sleep dimensions including hypoxic burden and chronic kidney disease: findings from the Multi-Ethnic Study of Atherosclerosis